Stay updated with breaking news from Technology Development Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ImmPACT Bio USA, Inc. ("ImmPACT BIO"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate in the 2023 Truist Securities BioPharma Symposium, to be held from November 8-9, 2023 in New York, NY.
The chip maker views the expansion as an important step towards regaining process technology leadership by 2025, which has been one of Intel CEO Pat Gelsinger's main goals.
Bone Biologics (OTC:BBLG – Get Free Report) is one of 129 publicly-traded companies in the “Medical Devices” industry, but how does it weigh in compared to its peers? We will compare Bone Biologics to related companies based on the strength of its risk, valuation, dividends, earnings, profitability, analyst recommendations and institutional ownership. Volatility and Risk […]
Bone Biologics (OTC:BBLG – Get Free Report) is one of 137 public companies in the “Medical Devices” industry, but how does it compare to its peers? We will compare Bone Biologics to similar companies based on the strength of its earnings, profitability, dividends, risk, analyst recommendations, institutional ownership and valuation. Risk & Volatility Bone Biologics […]
Bone Biologics (OTC:BBLG – Get Free Report) is one of 141 public companies in the “Medical Devices” industry, but how does it compare to its competitors? We will compare Bone Biologics to similar businesses based on the strength of its earnings, valuation, profitability, risk, analyst recommendations, institutional ownership and dividends. Valuation & Earnings This table […]